Literature DB >> 29472351

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.

Lisa M Rimsza1, Hongli Li2, Rita M Braziel3, Catherine M Spier4, Daniel O Persky5, Jennifer Dunlap3, Michael LeBlanc2, Nancy Bartlett6, John P Leonard7, Sonali M Smith8, Oliver W Press2, Jonathan W Friedberg9.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29472351      PMCID: PMC5865434          DOI: 10.3324/haematol.2017.175059

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method.

Authors:  R B Mann; C W Berard
Journal:  Hematol Oncol       Date:  1983 Apr-Jun       Impact factor: 5.271

Review 2.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

3.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

4.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Authors:  Alessandro Pastore; Vindi Jurinovic; Robert Kridel; Eva Hoster; Annette M Staiger; Monika Szczepanowski; Christiane Pott; Nadja Kopp; Mark Murakami; Heike Horn; Ellen Leich; Alden A Moccia; Anja Mottok; Ashwini Sunkavalli; Paul Van Hummelen; Matthew Ducar; Daisuke Ennishi; Hennady P Shulha; Christoffer Hother; Joseph M Connors; Laurie H Sehn; Martin Dreyling; Donna Neuberg; Peter Möller; Alfred C Feller; Martin L Hansmann; Harald Stein; Andreas Rosenwald; German Ott; Wolfram Klapper; Michael Unterhalt; Wolfgang Hiddemann; Randy D Gascoyne; David M Weinstock; Oliver Weigert
Journal:  Lancet Oncol       Date:  2015-08-06       Impact factor: 41.316

5.  Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.

Authors:  Ann S LaCasce; Michelle E Kho; Jonathan W Friedberg; Joyce C Niland; Gregory A Abel; Maria Alma Rodriguez; Myron S Czuczman; Michael M Millenson; Andrew D Zelenetz; Jane C Weeks
Journal:  J Clin Oncol       Date:  2008-09-02       Impact factor: 44.544

6.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

7.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad S Kahl; Peter Wood; Tim E Hawkins; David Macdonald; Mark Hertzberg; Yiu-Lam Kwan; David Simpson; Michael Craig; Kathryn Kolibaba; Samar Issa; Regina Clementi; Doreen M Hallman; Mihaela Munteanu; Ling Chen; John M Burke
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

8.  A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Authors:  Oliver W Press; Joseph M Unger; Lisa M Rimsza; Jonathan W Friedberg; Michael LeBlanc; Myron S Czuczman; Mark Kaminski; Rita M Braziel; Catherine Spier; Ajay K Gopal; David G Maloney; Bruce D Cheson; Shaker R Dakhil; Thomas P Miller; Richard I Fisher
Journal:  Clin Cancer Res       Date:  2013-10-15       Impact factor: 12.531

9.  Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies.

Authors:  G E Metter; B N Nathwani; J S Burke; C D Winberg; R B Mann; M Barcos; C R Kjeldsberg; C C Whitcomb; D O Dixon; T P Miller
Journal:  J Clin Oncol       Date:  1985-01       Impact factor: 44.544

10.  Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

Authors:  Oliver W Press; Joseph M Unger; Lisa M Rimsza; Jonathan W Friedberg; Michael LeBlanc; Myron S Czuczman; Mark Kaminski; Rita M Braziel; Catherine Spier; Ajay K Gopal; David G Maloney; Bruce D Cheson; Shaker R Dakhil; Thomas P Miller; Richard I Fisher
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 50.717

View more
  4 in total

1.  Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Authors:  Xiaoyu Qu; Hongli Li; Rita M Braziel; Verena Passerini; Lisa M Rimsza; Eric D Hsi; John P Leonard; Sonali M Smith; Robert Kridel; Oliver Press; Oliver Weigert; Michael LeBlanc; Jonathan W Friedberg; Min Fang
Journal:  Blood       Date:  2018-11-16       Impact factor: 22.113

Review 2.  Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.

Authors:  Kirsten M Boughan; Paolo F Caimi
Journal:  Curr Oncol Rep       Date:  2019-05-23       Impact factor: 5.075

Review 3.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Authors:  Rita Alaggio; Catalina Amador; Ioannis Anagnostopoulos; Ayoma D Attygalle; Iguaracyra Barreto de Oliveira Araujo; Emilio Berti; Govind Bhagat; Anita Maria Borges; Daniel Boyer; Mariarita Calaminici; Amy Chadburn; John K C Chan; Wah Cheuk; Wee-Joo Chng; John K Choi; Shih-Sung Chuang; Sarah E Coupland; Magdalena Czader; Sandeep S Dave; Daphne de Jong; Ming-Qing Du; Kojo S Elenitoba-Johnson; Judith Ferry; Julia Geyer; Dita Gratzinger; Joan Guitart; Sumeet Gujral; Marian Harris; Christine J Harrison; Sylvia Hartmann; Andreas Hochhaus; Patty M Jansen; Kennosuke Karube; Werner Kempf; Joseph Khoury; Hiroshi Kimura; Wolfram Klapper; Alexandra E Kovach; Shaji Kumar; Alexander J Lazar; Stefano Lazzi; Lorenzo Leoncini; Nelson Leung; Vasiliki Leventaki; Xiao-Qiu Li; Megan S Lim; Wei-Ping Liu; Abner Louissaint; Andrea Marcogliese; L Jeffrey Medeiros; Michael Michal; Roberto N Miranda; Christina Mitteldorf; Santiago Montes-Moreno; William Morice; Valentina Nardi; Kikkeri N Naresh; Yasodha Natkunam; Siok-Bian Ng; Ilske Oschlies; German Ott; Marie Parrens; Melissa Pulitzer; S Vincent Rajkumar; Andrew C Rawstron; Karen Rech; Andreas Rosenwald; Jonathan Said; Clémentine Sarkozy; Shahin Sayed; Caner Saygin; Anna Schuh; William Sewell; Reiner Siebert; Aliyah R Sohani; Reuben Tooze; Alexandra Traverse-Glehen; Francisco Vega; Beatrice Vergier; Ashutosh D Wechalekar; Brent Wood; Luc Xerri; Wenbin Xiao
Journal:  Leukemia       Date:  2022-06-22       Impact factor: 12.883

Review 4.  Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.

Authors:  Matthew J Matasar; Stefano Luminari; Paul M Barr; Stefan K Barta; Alexey V Danilov; Brian T Hill; Tycel J Phillips; Mats Jerkeman; Massimo Magagnoli; Loretta J Nastoupil; Daniel O Persky; Jessica Okosun
Journal:  Oncologist       Date:  2019-07-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.